期刊文献+

HPLC法测定安立生坦片中有关物质 被引量:1

Determination of related substances in ambrisentan tablets by HPLC
原文传递
导出
摘要 目的:建立高效液相色谱法测定安立生坦片中有关物质。方法:采用安捷伦ZORBAX SB-Aq(4.6mm×250 mm,5μm)色谱柱,流动相A为5 mmol·L^(-1)磷酸二氢钾溶液(p H 3.0),流动相B为乙腈,以1.0m L·min^(-1)的流速进行梯度洗脱,检测波长为210 nm,柱温25℃,以自身对照法测定安立生坦片中有关物质。结果:安立生坦与各杂质及降解产物能够完全分离(分离度大于2.0);供试品溶液在24 h内稳定性良好;安立生坦和2-羟基-3-甲氧基-3,3-二苯基丙酸(杂质A)、(S)-1-(4-氯苯基)乙胺(杂质B)、3,3二苯基-2,3-环氧丙酸甲酯(杂质C)、2-羟基-3-甲氧基-3,3二苯基丙酸甲酯(杂质D)、4,6-二甲基-2-甲基-磺酰嘧啶(杂质E)和4,6-二甲基-2-(2,2-二苯基-乙烯氧基)嘧啶(杂质F)的定量限分别为0.66、0.64、0.65、1.31、0.65、0.63和1.32 ng,相对校正因子分别为1.00、1.08、2.20、1.09、1.10、2.54和1.07;安立生坦质量浓度在0.5~5.0μg·m L^(-1)范围内线性良好(r>0.999 9),各杂质质量浓度在0.125~2.5μg·m L^(-1)范围内线性良好(r>0.999),杂质加样回收率(n=9)在95.8%~103.7%之间;重复性和中间精密度符合规定。经检测,3批安立生坦片中杂质A含量均为0.01%。结论:经验证本方法准确、灵敏,精密度高,耐用性和专属性强,可用于安立生坦片中有关物质的测定。 Objective:To establish an HPLC method for the determination of related substances in ambrisentan tablets.Methods:The substances were analyzed by using an Agilent ZORBAX SB-Aq column(4.6 mm×250 mm,5 μm) with gradient elution by the mobile phase A(potassium dihydrogen phosphate buffer of p H 3.0,5 mmol·L^-1) and mobile phase B(acetonitrile).The flow rate was 1.0 m L·min^-1,the detection wavelength was 210 nm,and the column temperature was 25 ℃.The determination of related substances in ambrisentan tablets was analyzed with self-contrast method.Results:Ambrisentan was separated completely from the impurities and degradation products(the resolution was above 2.0).The test solution was stable for at least 24 h.The LOQ of ambrisentan and 2-hydroxy-3-methoxy-3,3-diphenyl propanoic acid(impurity A),(S)-1-(4-chlorophenyl)ethylamine(impurity B),3,3-diphenyloxirane-2-carboxylic acid methyl ester(impurity C),2-hydroxy-3-methoxy-3,3-diphenyl propanoic acid methyl ester(impurity D),4,6-dimethyl-2-methylsulfonyl-pyrimidine(impurity E),2-[(2,2-diphenylvinyl)oxy]-4,6-dimethylpyrimidine(impurity F) were 0.66,0.64,0.65,1.31,0.65,0.63,and 1.32 ng and the relative correction factors were 1.00,1.08,2.20,1.09,1.10,2.54,and 1.07.The mass concentration of ambrisentan was in good linearity within the range of 0.5-5.0 μg·m L^-1(r=0.999 9),and the mass concentration of impurities obtained good linearity within the range of 0.125-2.5 μg·m L^-1(r 0.999).The recoveries of the impurities(n=9) were between 95.80% and 103.69%.The repeatability and intermediate precision completely met the requirements.The impurity A contents in three batches of ambrisentan tablets were 0.01%,0.01%,and 0.01%,respectively.Conclusion:By method validation,the established method is accurate,sentitive with good precision,durablity and specificity,and can be used in the determination of related substances in ambrisentan tablets.
出处 《药物分析杂志》 CAS CSCD 北大核心 2016年第5期895-901,共7页 Chinese Journal of Pharmaceutical Analysis
关键词 安立生坦片 2-羟基-3-甲氧基-3 3-二苯基丙酸 (S)-1-(4-氯苯基)乙胺 3 3二苯基-2 3-环氧丙酸甲酯 2-羟基-3-甲氧基-3 3二苯基丙酸甲酯 4 6-二甲基-2-甲基-磺酰嘧啶 4 6-二甲基-2-(2 2-二苯基-乙烯氧基)嘧啶 有关物质检测 溶液稳定性 高效液相色谱法 自身对照法 ambrisentan tablets 2-hydroxy-3-methoxy-3 3-diphenyl propanoic acid (S)-1-(4-chlorophenyl) ethylamine 3 3-diphenyloxirane-2-carboxylic acid methyl ester 2-hydroxy-3-methoxy-3 3-diphenyl propanoic acid methyl ester 4 6-dimethyl-2-methylsulfonyl-pyrimidine 2-[(2 2-diphenylvinyl)oxy]-4 6-dimethylpyrimidine related substances detection solution stability HPLC self-contrast method
  • 相关文献

参考文献6

二级参考文献70

  • 1BOLLI MH, MARFURT J, GRISOSTOMI C, et al. Novel benzo [ 1,4] diazepin-2-one derivatives as endothelin receptor antagonists[ J]. J Med Chem ,2004,47 ( 11 ) :2776 - 2795.
  • 2CLOZEL M. Effects of bosentan on cellular processes involved in pulmonary arterial hypertension: Do they explain the long-term benefit? [J]. AnnMed,2003,35(8): 605 -613.
  • 3UHLMANN D, GABEL G, LUDWIG S, et al. Effects of ET(A) receptor antagonism on proinflammatory gene expression and microcirculation following hepatic ischemia/reperfusion[ J]. Microcirculation ,2005,12 ( 5 ) :405 - 419.
  • 4UHLMANN D, GLASSER S, GABEL G, et al. Improvement of postischemic hepatic microcirculation after endothelin A receptor blockade-endothelin antagonism influences platelet-endothelium interactions [ J ]. J Gastrointest Surg,2005,9 ( 2 ) : 187 - 197.
  • 5UHLMANN D, GABEL G, ARMANN B, et al. Attenuation of proinflammatory gene expression and mierocirculatory disturbances by endothelin A receptor blockade after orhotopic liver transplantation in pigs[ J]. Surgery,2006,139( 1 ) :61 -72,
  • 6GABEL G, UHLMANN D, TEUPSER D, et al. Influence of a selective endothelin (A) receptor antagonist on the quantitative mRNA expression and the immunohistochemishry of vasoactive mediators after pancreas transplantation [ J ]. Transplant Proc, 2003,35(6) :2137 -2138.
  • 7WITZIGMANN H, LUDWIG S, ESCHER E, et al. Administration of a selective endothelin-A receptor antagonist (BSF 208075) improves hepatie warm ischemia/reperfusion injury in pigs [ J ]. Transplant Proc,2002,34 ( 6 ) : 2387 - 2388.
  • 8KIRCHENGAST M. Endothelin receptor blockade and in-stent restenosis[ J ]. J Cardiovasc Pharmacol, 2001,38 ( Suppl 2 ) : S31 - S34.
  • 9KIRCHENGAST M, LUZ M. Endothelin receptor antagonists: Clinical realities and future directions[ J]. J Cardiovasc Pharmacol,2005,45(2) :182 - 191.
  • 10REMUZZI G, PERICO N, BENIGNI A. New therapeutics that antagonize endothelin : Promises and frustrations [ J ]. Nat Rev Drug Discov,2002, 1 (6) : 986 - 1001.

共引文献12

同被引文献10

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部